Abstract: An oil-in-water emulsion useful as a delivery vehicle of hydrophobic ingredients such as pharmaceutical drugs and cosmetic active agent; wherein the emulsion particles have a net positive charge (i.e. a positive zeta potential).

Abstract: The present invention pertains to hydrolysis-optimized isotonic lipid emulsions comprising medium-chain triglycerides (MCT), vegetable oils and fish oil, as well as their use for parenteral nutritition.

Abstract: The present invention relates to a delivery system which includes a bioactive drug or cosmetic substance presented in the form of submicron oil spheres alone, or drugs or cosmetic substances in a combination with the oil spheres in an aqueous suspension or emulsion. Optionally, a skin penetration enhancer may be included in such formulations. Such preparations achieve improved bioavailability and exert larger pharmacological effects than an equivalent dose of the drug or cosmetic formulated in conventional creams, lotions or oleaginous bases.

Abstract: A sprayable or solid biodegradable wax carrier for insect pheromones and a method for constant release rate of the pheromone from the biodegradable wax. A composition comprising a pheromone and paraffin wax formulated as an aqueous emulsion or a solid suitable for application to a surface of a tree or crop for mating disruption of insect pests. Pheromone is released by diffusion or by partitioning from the biodegradable wax carrier or by pheromone exposure due to the biodegradable wax carrier degradation.

Abstract: A novel formulation which contains about 2-60% by calories of a C.sub.20 or longer .omega.3 fatty acid moiety and about 2-60% by calories of an arachidonic acid moiety has been developed. This formulation is particularly useful for restoring arachidonic acid levels, increasing immunity or minimizing risk of infection in critically ill patients, and treating functional essential fatty acid deficiency in patients suffering from end stage liver disease. A structured lipid which has a C.sub.20 or longer .omega.3 fatty acid moiety and an arachidonic acid moiety has also been developed.

Abstract: An eye drop composition for alleviation of dry eye related symptoms in dry eye patients and contact lens wearers includes an emulsion of a higher fatty acid glyceride, polysorbate 80 and an emulsion stabilizing amount of Pemulen.RTM. in water suitable for topical application to ocular tissue.

Abstract: The inventions relates to carboxamidopolysiloxanes in cosmetic formulations, especially in skin-, hair-, nail- or mouthcare compositions. The cosmetic state is being improved: wet combability, combing force and static charge.

Abstract: The present invention relates to a mixture of a silicone wax, a silicone fluid and two long chain lactate molecules which is effective in reducing the tacky feel of compositions. The present invention is suitable for use in creams, gels, lotions and salves that are applied to the skin.

Abstract: Disclosed is an infusion preparation for nutrient supply use. It comprises a sugar, amino acids, electrolytes and a fat emulsion. It has an excellent shelf life without causing precipitation, denaturation and the like in spite of the simultaneous presence of these components. Also disclosed is a container filled with infusion liquids comprising a first and a second compartments separated from each other by a separation means, wherein an infusion liquid containing a fat emulsion and a sugar is included in the first compartment and another infusion liquid containing amino acids and electrolytes is included in the second compartment. Further disclosed are an infusion preparation comprising a fat emulsion and a sugar, and an infusion preparation comprising amino acids and electrolytes.

Abstract: A self-emulsifying oily formulation (SEOF) comprising an oil component and a surfactant, the SEOF being characterized in that the oil component comprises an oily carrier and a cationic lipid and optionally, a lipophilic oily fatty alcohol, the oil-in-water emulsion which forms upon mixture of the SEOF, having oily droplets which are positively charged.

Abstract: Concentrated aqueous liquid disinfectant compositions which exhibit a blooming effect when diluted in a larger volume of water are provided. The concentrate compositions include non-phenolic constituents to provide a disinfecting effect, and are non pine-oil containing. Working strength dilutions of the concentrated aqueous liquid disinfectant compositions are effective against gram positive type pathogenic bacteria such as Staphylococcus aureus, as well as gram negative type pathogenic bacteria such as Salmonella choleraesuis.

Abstract: A pearlescent concentrate containing: (a) a pearlescent agent; (b) a cocamide monoethanolamine having a specific carbon chain distribution; and (c) water.

Abstract: The present invention relates to a cosmetic or dermatological composition comprising an emulsion of oil-in-water type formed of oily globules which are each provided with a lamellar liquid crystal coating and are dispersed in an aqueous phase. Each oily globule containing at least one lipophilic compound which is cosmetically or dermatologically active is individually coated with a monolamellar or aligolamellar layer obtained from at least one lipophilic surface-active agent, from at least one hydrophilic surface-active agent and from at least one ionic amphiphilic lipid imparting to the emulsion a pH ranging from 5.5 to 7.5, the coated oily globules having a mean diameter of less than 500 nanometers.

Abstract: A method for the use of short chain fatty acids containing lipids in clinical nutrition to maintain gastrointestinal integrity and function in conditions where normal short chain fatty acid substrates, provided by bacterial fermentation of carbohydrates, is inadequate due to the clinical condition of the patient. By providing the short chain fatty acid in a lipid form of free fatty acid, triglyceride, diglyceride, monoglyceride, phospholipid, or cholesterol ester one is able to avoid the clinical defect and allow the gastrointestinal tract to continue to maintain its integrity and function. The short chain fatty acids of the present invention can be provided either in enteral preparations or parenteral preparations.The short chain fatty acids can be provided by hydrolysis of a structure such as: ##STR1## wherein R--COO--, R'--COO--, and R"--COO-- represent either the same or different short chain fatty acids.

Abstract: Adjuvants for systemic fungicides in the form of a stable microemulsion comprise water, a mixture of methyl esters of fatty acids obtained by the transesterification of vegetable oils, an anionic surface-active agent, at least one non-ionic surface-active agent with an HLB of between 13-18 and a cloud point of >65.degree. and at least one non-ionic surface-active agent with an HLB of between 10 and 12. These adjuvants, which can additionally contain conventional components and/or formulation additives, improve the activity of systemic fungicides belonging to different chemical groups.

Abstract: A cosmetic or pharmaceutical composition containing an emulsifier comprising an ester of palmitic acid and technical grade triglycerol with the proviso that the monoester content of the ester is from 30% to 50% by weight.

Abstract: A transdermal therapeutic system comprising the active substance estradiol and having a layered structure of a backing layer which is impermeable to active substances and moisture, and active substance-containing matrix, and, if necessary, a removable protective layer covering the matrix, is characterized by the fact that the matrix comprises glycerol either comprising a maximum of 1%-wt. of water or being substantially free from water.

Abstract: A pharmaceutical preparation comprising a stable, surface-active emulsion or dispersion of a pharmaceutical agent incorporated into an emulsion (i) having a hydrophobic discontinuous phase of a long chain carboxylic acid or ester or alcohol thereof dispersed in an aqueous phase or (ii) having a hydrophilic discontinuous phase dispersed in a hydrophobic phase of a long chain carboxylic acid or alcohol thereof. The emulsion with pharmaceutical agent is incorporated into a pharmaceutical carrier suitable for oral delivery.

Abstract: Homogeneous antimicrobial compositions and antimicrobial wet wipes and lotions which include the antimicrobial compositions are described. The homogeneous antimicrobial composition includes at least about 50 weight percent water based on a total weight of the composition and an effective amount of a hydrophobic antimicrobial agent which is uniformly dispersed in the composition. The antimicrobial wet wipe includes from about 150 to about 600 weight percent of the antimicrobial composition based on the dry weight of the wipe. The homogenous antimicrobrial composition may include, based upon the total weight of the composition, (a) from about 0.01 to about 3.0 weight percent of a hydrophobic antimicrobrial agent; (b) from about 1.0 to about 15.0 weight percent of an amide; (c) from about 1.0 to about 30.0 weight percent of a surfactant; and (d) from about 50 to about 98 weight percent water.

Abstract: A pharmaceutical preparation for oral acyclovir delivery comprising a stable, hydrophobic emulsion comprising continuous phase of a hydrophobic material selected from the group consisting of a long chain carboxylic acid or ester or alcohol thereof dispersed in an aqueous phase or (ii) having a hydrophilic discontinuous phase dispersed in a hydrophobic phase of a long chain carboxylic acid or alcohol thereof. The emulsion with acyclovir is incorporated into a pharmaceutical carrier suitable for oral delivery.

Abstract: The present invention relates to the use of a non-ionic surface-active agent or an emulsion for the reduction of the hemolytic effects of an amphiphilic compound. There is also provided a method for reducing the hemolytic effects of an amphiphilic compound which comprises formulating said compound with a non-ionic surface-active agent or in the form of an emulsion.

Abstract: A novel complex containing an ampholytic and/or semi-polar surfactant as well as a higher fatty acid, and if necessary, a clay mineral, and an emulsified composition containing this complex.

Abstract: This invention pertains to therapeutic wound healing compositions for protecting and resuscitating mammalian cells (Embodiment One (I)). This invention also pertains to therapeutic antiviral-wound healing compositions for reducing viral titers and increasing the proliferation and resuscitation rate of mammalian cells (Embodiment Two (II)). In a first aspect of Embodiment One (I.A), the therapeutic wound healing composition comprises (a) pyruvate, (b) an antioxidant, and (c) a mixture of saturated and unsaturated fatty acids. In a second aspect of Embodiment One (I.B), the therapeutic wound healing composition comprises (a) pyruvate, (b) lactate, and (c) a mixture of saturated and unsaturated fatty acids. In a third aspect of Embodiment One (I.C), the therapeutic wound healing composition comprises (a) an antioxidant and (b) a mixture of saturated and unsaturated fatty acids. In a fourth aspect of Embodiment One (I.

Abstract: A detergent composition comprising:(A) glycerol derivative having the following Formula (I) ##STR1## (B) a water-soluble polyhydric alcohol; and (C) at least one surfactant selected from the group consisting of an anionic surfactant, wherein component (A) and component (C) are in a ratio of from 2:1 to 1:100 by weight. When the detergent composition is used to clean skin, the skin remains moisturized after cleaning without stickiness or tackiness and without excess degreasing or dryness.

Abstract: An antifoaming agent which comprises, as the main component, one or more polyglycerol fatty acid esters having a specific degree of polymerization of polyglycerol, specific fatty acid types and a specific saponification value, as well as a canned drink containing the same. The antifoaming agent exhibits an excellent antifoaming effect and solve the problem of blow-off and splash of canned drinks.

Abstract: A polar lipid composition of plant origin is provided for conveying an active agent and/or making it penetrate into a target cell. The composition is characterized in that it is comprised of an injectable, intra-articular, topical or ingestible aqueous emulsion of a polar lipid mixture rich in phospholipids, in glycolipids and in ceramides, having a composition which is substantially similar to that of the polar lipid constituents of lipid cytomembranes of cells. The mixture is obtained from a plant compound such as cereal flour or an extract such as bran or lipids extracted from cereals by means of chlorinated solvents.

Abstract: A water-in-oil type oil adjuvant vaccine comprises 20 to 90% by weight of an oil phase A) which is in a liquid state at ordinary temperature; 0.5 to 30% by weight of an emulsifying agent comprising a non-ionic surfactant B) which is a partial ester derived from a polyhydric alcohol carrying at least three hydroxyl groups and a fatty acid and which is in a liquid state at 40.degree. C. and a polyoxyethylene (20 to 60 moles) hydroxy fatty acid triglyceride C); and 5 to 75% by weight of an aqueous phase D) containing a biologically acceptable and effective amount of antigens, and optionally E) 0.01 to 10% by weight of an amino acid or a salt thereof and 0.01 to 10% by weight of a non-reducing sugar or a sugar alcohol having at least 5 hydroxyl groups in the molecule. In addition, a water-in-oil-in-water type oil adjuvant vaccine comprises the foregoing water-in-oil type oil adjuvant vaccine as an internal phase and an outer aqueous phase F) comprising 0.

Abstract: Emulsifiers particularly suitable for the production of storable, high-viscosity and sensorially light o/w emulsions contain from about 43% to about 99% by weight of an alkyl and/or alkenyl oligoglycoside and from about 1% to about 57% by weight of a fatty alcohol.

Abstract: The new pharmaceutical and diagnostic compositions comprise antibody-aggregates and hydrophobic drug or marker molecules. The drug or marker molecules are solubilized inside micelle-like antibody-aggregates. In a process for preparing such types of compositions, hydrophobic residues are attached to the antibodies in the presence of a surface active agent. After removal of this agent the hydrophobic drug or marker molecules are solubilized inside the resulting antibody aggregates. A method for targeting molecules towards specific cells and sites within a living body is also disclosed.

Abstract: This invention relates to compositions comprising highly fluorinated, chloro-substituted, non-cyclic organic compounds having 7 to 9 carbon atoms and to processes of making and using them. More particularly, this invention relates to emulsions comprising those highly fluorinated, chloro-substituted organic compounds. This invention also related to emulsion comprising noncyclic perfluorochlorethers having 7 to 10 carbon atoms, preferably 7 to 9 carbon atoms. These novel emulsions have various medical and oxygen transport applications. They are especially useful medically as contrast media, for various biological imaging modalities such as nuclear magnetic resonance, ultrasound, x-ray, computed tomography, .sup.19 F-magnetic resonance imaging, and position emission tomography, as oxygen transport agents or "artificial bloods," in the treatment of heart attack, stroke, and other vascular obstructions, as adjuvants to coronary angioplasty and in cancer radiation treatment and chemotherapy.

Abstract: A composition which is one comprising water, a wax ester, and at least one of other components usable in cosmetics, and contains an ester composed of C.sub.18-34 fatty acid--C.sub.18-44 higher alcohol, and an amphoteric surface active agent, and can further contain a C.sub.18-34 higher fatty acid.It is possible to provide an intermediate composition for cosmetics and the above final product which are excellent in feelings in use to skin, and have physical and chemical characteristics for making their stable storage possible, and can be advantageously used particularly for foundation, lipstick, eye shadow, etc.

Abstract: Bioadhesive microemulsions or liposomic dispersions containing proteinaceous substances, especially calcitonin, that allow the systemic, local or topical administration of drugs by transmucosal route are described. This type of administration shows some considerable advantages of activity, tolerability, dosage individualization and drug stability.

Abstract: The present invention relates to dry, stable compositions which can be reconstituted to form pharmaceutical or cosmetic emulsions, and to methods for making such compositions. An emulsion is formed from about 0.2 to 25 weight percent of a first component of an oil, about 0.1 to 5 weight percent of a second component of an emulsifier, about 0.25 to 25 weight percent of a cryoprotectant of an amino compound, such as one or more amino acids, peptides or protein hydrolysates, and an aqueous component, wherein the amino compound is present in an amount that is equal to or greater than that of the first component. Optionally, a co-emulsifier, a suspension agent, a preservative, an antioxidant and a drug can be added to these emulsions. Thereafter, the emulsion is lyophilized to form dry compositions that have from about 40 to about 90 weight percent of the amino compound; from about 0.1 to about 20 weight percent of the emulsifier; and from about 0.2 to about 40 weight percent of the oily component.

Abstract: A composition of a mixture of nonionic surfactants in water-in-oil emulsion vaccines allows the use of animal, vegetable, and synthetic oils as well as mineral oil and pristane. These non-mineral oil vaccines are as efficacious as mineral oil-containing vaccines without the problems associated with the use of mineral oil.

Abstract: Balanced emulsifier blends that provide a stable oil-in-water emulsion of preselected viscosity are disclosed. The emulsifier blend contains an acyl lactylate as the primary emulsifier and a nonionic surfactant as the coemulsifier. A method of preparing an oil-in-water emulsion having a preselected viscosity also is disclosed.

Abstract: The present invention provides an enteral nutritional formulation that meets the nutrient requirements of patients with wounds. The present invention meets the unique nutrient needs of the acute or chronic patient that are generated due to tissue repair and healing requirements of wounds. To this end, in an embodiment, the present invention provides a method for providing nutritional support to a patient with an acute or chronic wound comprising the step of administering a therapeutically effective amount of composition comprising a protein source including an arginine source and a proline source in the ratio by weight of approximately 1:0.5 to about 4:1. The composition may also include a carbohydrate source, a lipid source including an appropriate n6:n3 ratio, and at least the U.S. RDA for vitamins and minerals provided in an amount of formula supplying 1000 kcal, with vitamin A, beta-carotene, vitamin C, vitamin E, thiamine, pyridoxine, biotin and zinc being supplied in amounts above the U.S. RDAs.

Abstract: The present invention provides a composition as well as method for providing nutrition to renal patients. Pursuant to the present invention, the enteral composition includes an effective amount of a protein source including whey protein and free amino acids that provide essential as well as nonessential amino acids. The composition is calorically dense and has a moderate osmolality.

Abstract: The present invention provides an enteral nutritional formulation that meets the nutrient requirements of intensive care patients who may have compromised absorption capacity. The present invention meets the unique nutrient needs of the patient that are generated due to tissue repair and healing requirements. To this end, in an embodiment the present invention provides a method for treating and/or providing nutritional support to intensive care patients comprising the steps of administering a therapeutically effective amount of a composition comprising: a protein source; a carbohydrate source; and a lipid source including a source of medium chain triglycerides, a source of omega-3 fatty acids, and a source of omega-6 fatty acids.

Abstract: A process for producing a storage-stable, fine-particle wax dispersion by heating a mixture containing(A) 10% to 80% by weight of a wax,(B) 0.5% to 30% by weight of a hydrophilic nonionic dispersant having an HLB value of 8 to 18, and(C) 1% to 30% by weight of a hydrophobic co-dispersant selected from the group consisting of fatty alcohols containing 12 to 22 carbon atoms and partial esters of polyols containing 3 to 6 carbon atoms with fatty acids containing 12 to 22 carbon atoms,with the proviso that the weight ratio of component (B) to component (C) is in the range from 0.5:1 to 20:1, in the presence of 15% to 85% by weight of water to a temperature above the melting point of the mixture of components (A) to (C) to form a dispersion, heating the dispersion to its phase inversion temperature, and then cooling the dispersion to a temperature below its phase inversion temperature.

Abstract: The present invention provides an enteral nutritional formulation that meets the nutrient requirements of intensive care patients who may have compromised absorption capacity. The present invention meets the unique nutrient needs of the patient that are generated due to tissue repair and healing requirements. To this end, in an embodiment the present invention provides a method for providing nutritional support to intensive care patients comprising the steps of administering a therapeutically effective amount of a composition comprising: a protein source; a carbohydrate source; and a lipid source including a source of medium chain triglycerides, a source of omega-3 fatty acids, and a source of omega-6 fatty acids.

Abstract: Methods of incorporating a hydrophobic substance into an aqueous solution in a manner which provides a homogeneous composition are described. The hydrophobic substance is at least partially dissolved in an amide to provide an active mixture. The active mixture is then combined with an aqueous solution to form a composition which may then be mixed for a sufficient amount of time to obtain a uniform dispersion. In a particular aspect, the aqueous solution may include a surfactant.

Abstract: A lipid emulsion which comprises (A) an oil component, (B) an emulsifying agent containing yolk lecithin and/or soybean lecithin, and (C) water, wherein the lipid emulsion further comprises citric acid or a pharmaceutically acceptable salt thereof and at least one member selected from the group consisting of methionine, phenylalanine, serine, histidine and pharmaceutically acceptable salts thereof, provided that it does not simultaneously contain methionine and phenylalanine. The addition of citric acid and histidine, methionine, phenylalanine and/or serine to a lipid emulsion containing natural lecithin as an emulsifying agent permits the prevention of change of color and formation of oil drops associated with the conventional natural lecithin-containing lipid emulsion due to the synergistic effect of the foregoing additives.

Abstract: An oil-in-water type emulsion composition comprising: an amphiphile and a surfactant selected from the substances which can form a gel in an amphiphatic substance-surfactant-water system at a temperature of not lower than ordinary temperatures; oil and water, wherein substantially the total amount of amphiphile and surfactant exist on the boundary surfaces of emulsion particles. The emulsion composition has both the physical properties close to those of an aqueous solution and a creamy feel at the time of use.

Abstract: Gugulipid (a lipophilic ethyl acetate extract from C. mukul or C. wightii) and an alcoholic fraction of gugulipid as antisebum and/or antioxidant active in cosmetic skin care compositions and methods is disclosed. Gugulipid from C. mukul and its alcoholic fraction are capable of delivering dual benefit to the skin: controlling or preventing sebum secretion (oily skin conditions) and protecting the skin from free radical damage.

Abstract: A clove oil formulation which inhibits soil-borne fungal diseases is disclosed. The formulation includes about 70-90% by weight rectified clove oil, and about 2-30% by weight surfactant. The surfactant includes about 15-95% by weight nonionic compounds such as ethoxylated monoglycerides, ethoxylated diglycerides, ethoxylated alcohols, silicone glycol copolymers, sorbitan fatty acid esters, ethoxylated alkyl phenols, ethylene oxide block copolymers, and propylene oxide block copolymers. The surfactant further includes about 5-85% by weight anionic compounds such as amine alkylaryl sulfonate, calcium alkylaryl sulfonate and phosphate esters. The formulation may also include up to about 30% by weight of a solvent such as alcohol, esters, glycol ethers, mineral oil, methyl esters and hydrocarbon solvents.

Abstract: The liquid of the present invention can provide good cleansing, lather and good sensory feel and yet surprisingly provide a lipid moisturizing benefit via deposition of the lipid on the skin of the user. The liquid composition is stable and on a macro scale is homogeneous. The dual cleansing and lipid moisturizing liquid composition of this invention comprises: (1) about 5 parts to about 30 parts of a lipid skin moisturizing agent; (2) about 1 to about 15 parts of an ethylene glycol fatty acid ester; (3) from about 0.05 parts to about 3 parts of a selected water dispersible gel forming polymer (4) from about 5 parts to about 30 parts of a lathering synthetic surfactant, and; (5) water, and wherein said synthetic surfactant and any soap has a combined CMC equilibrium surface tension value of from 15 to 50, and wherein said lathering skin cleansing liquid composition has a Lipid Deposition Value (LDV) of from about 5 to about 1000 .mu.g of lipid per sq. cm of skin.

Abstract: A cosmetic or dermatological composition with a depigmenting action comprises derivatives of 2,5-dihydroxyphenylcarboxylic acids, their homologs, and their salts, with the derivatives having the following structural formula: ##STR1## wherein: R.sub.1 represents OR.sub.5, OH, or ##STR2## R.sub.5 is a linear or branched C.sub.1 -C.sub.20 alkyl radical, a linear or branched C.sub.2 -C.sub.20 alkenyl radical, or a C.sub.1 -C.sub.20 alkyl radical substituted by one or more hydroxy or alkoxy groups;r' and r", identical or different, represent a hydrogen atom, a C.sub.1 -C.sub.20 alkyl radical, a C.sub.2 -C.sub.6 hydroxyalkyl radical, or a C.sub.3 -C.sub.6 polyhydroxyalkyl, or r' and r" taken together, with the nitrogen atom, form a heterocycle;the number of carbon atoms in the --(CH.sub.2).sub.n --COR.sub.1 chain is less than or equal to 21;R.sub.2 and R.sub.3, identical or different, represent a hydrogen atom, a linear or branched C.sub.1 -C.sub.4 alkyl radical, or a C.sub.1 -C.sub.4 alkoxy; R.sub.

Abstract: The present invention pertains to therapeutic bioadhesive-wound healing compositions useful for treating wounds and increasing the proliferation and resuscitation rate of mammalian cells. The compositions comprise a bioadhesive agent and a therapeutically effective amount of a wound healing composition. In one embodiment the wound healing composition comprises (a) pyruvate; (b) an antioxidant; and (c) a mixture of saturated and unsaturated fatty acids. The therapeutic bioadhesive-wound healing compositions may further comprise medicaments such as antiviral agents, antikeratolytic agents, anti-inflammatory agents, antifungal agents, antibacterial agents, immunostimulating agents, and the like. The bioadhesive-wound healing compositions may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the bioadhesive-wound healing compositions and the pharmaceutical products in which the compositions may be used.

Abstract: A dermatological or cosmetic composition for skin care containing 0.01 to 30% by weight of at least one ceramide and 1 to 15% by weight of linoleic acid useful for restoring the barrier function of the stratum corneum of dry or very dry skin.

Abstract: Orally or rectally administrable formulations of biologically active material comprise a water-in-oil microemulsion, wherein the hydrophilic phase of the microemulsion comprises the biologically active material and the hydrophobic phase comprises chylomicra or material capable of forming chylomicra in the intestinal mucosa after administration. The biologically active material may be any of a wide range of substances including insulin, calcitonin and somatotrophin or growth hormone. Formulations of the invention are particularly suitable for the oral administration of insulin in the treatment of diabetes.